A Phase 1 clinical trial for NDI (AVP-R) is now enrolling
- Alex Tamayo Wolf
- Jul 13
- 2 min read
For years, the honest answer to "is anyone working on a treatment for NDI?" was: not really, not yet. That answer has changed.
A Phase 1 clinical trial is now enrolling for NDI-5001, an investigational treatment for nephrogenic diabetes insipidus (NDI, also known as AVP-R). It is sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. The first research site is in Jacksonville, Florida, and more may open as the trial progresses.
This is a milestone for our community. It is also, deliberately, a modest one — and we want to be precise about what it is and what it isn't, because you deserve that more than you deserve excitement.
What "investigational" and "Phase 1" actually mean
Investigational means the treatment is being studied and is not approved. It can only be given inside a clinical trial. Nobody — not the sponsor, not the researchers, not us — is claiming it works.
Phase 1 is the earliest stage of human testing. Its purpose is to look at safety, how well the drug is tolerated, and how the body absorbs and processes it. Phase 1 is not designed to prove that a treatment is effective. That question comes later, and only if the early results support going further.
Who this phase is for
Phase 1 has narrow eligibility criteria set by the sponsor. As registered, this phase is enrolling adult males, ages 18 to 55, with X-linked congenital NDI (caused by mutations in the vasopressin V2 receptor).
That will exclude many people reading this — including women, children, and people whose NDI is autosomal or acquired. We know how that lands. It is genuinely frustrating to finally see a trial and find the door isn't open to you yet.
If you don't fit Phase 1, still add your name
Trials expand. Later phases routinely have different criteria, and new research sites open in new places. The single most useful thing you can do — whether or not you fit today's criteria — is put your name forward, so a research site can reach you as things change.
A community that is already identified and ready is a community that moves faster when the next door opens.
What happens when you add your name
The first step is a short interest form. It is not enrollment, and it is not a commitment of any kind.
You answer some questions about your diagnosis and where you're located. A research site reviews what you've submitted and follows up with you if you may be a fit. You can stop at any point, and you can ask us to remove your information at any time.
Your information is shared only with the research site handling your screening. It is not sold, and it is not given to anyone else.